3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺
3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺
3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺 性质
| 沸点 | 646.9±55.0 °C(Predicted) |
|---|---|
| 密度 | 1?+-.0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMF:30.0(最大浓度 mg/mL);78.44(最大浓度 mM) DMF:PBS (pH 7.2) (1:2):0.33(最大浓度 mg/mL);0.86(最大浓度. mM) DMSO:44.22(最大浓度 mg/mL);115.63(最大浓度 mM) 乙醇:1.5(最大浓度 mg/mL);3.92(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 4.81±0.40(Predicted) |
3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺 用途与合成方法
IC50: 10 nM (KDM4B)
NCGC00244536 displays high selectivity for the fast-growing AR-negative PC3 cells (IC 50 =40 nM) and over 100-fold selectivity against the immortalized prostate epithelial cell lines PrEC1 and PrEC4. NCGC00244536 effectively inhibits AR-positive cell lines, including LNCaP and VCaP, with IC 50 s in the sub-micromolar range, and abolishes androgen-stimulated LNCaP cell growth. NCGC00244536 is also potent in inhibiting the growth of other cancer cell lines, including the breast cancer cell lines MDA-MB2 and MCF-7, with micromolar IC 50 s.
Treatment with NCGC00244536 results in significant inhibition of tumor growth and animals do not exhibit any major toxicity and appear to be normal. Histological data clearly indicate that NCGC00244536-treated tumors have significant amount of cell apoptosis, necrosis, and fibrosis.
3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-101799 | 3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺 | 2003260-55-5 | 1mg | 1100 |
| 2024-04-30 | HY-101799 | 3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺 | 2003260-55-5 | 10mM * 1mLin DMSO | 2777 |
